Adjuvant irradiation to prevent keloidal fibroproliferative growth should be standard of care

Br J Dermatol. 2017 Dec;177(6):e327-e328. doi: 10.1111/bjd.15667. Epub 2017 Nov 29.

Authors

M K Ramirez-Fort^{1

2

3}, B Meier⁴, A Feily⁵, S L Cooper¹, C S Lange³

Affiliations

¹ Radiation Oncology, Medical University of South Carolina, Charleston, SC, U.S.A.
² Urology, Weill Cornell Medicine, New York, NY, U.S.A.
³ Radiation Oncology, State University of New York Downstate Medical Center, Brooklyn, NY, U.S.A.
⁴ Dermatology, University Hospital of Zurich, Zurich, Switzerland.
⁵ Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran.

PMID: 28730611
DOI: 10.1111/bjd.15667

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Aged
Cell Proliferation / radiation effects
Child
Child, Preschool
Dose-Response Relationship, Radiation
Electrons / therapeutic use
Humans
Infant
Keloid / radiotherapy*
Middle Aged
Patient Satisfaction
Radiotherapy, Adjuvant
Standard of Care
Young Adult